Literature DB >> 15604269

Inhibition of Chk1 by CEP-3891 accelerates mitotic nuclear fragmentation in response to ionizing Radiation.

Randi G Syljuåsen1, Claus Storgaard Sørensen, Jesper Nylandsted, Claudia Lukas, Jiri Lukas, Jiri Bartek.   

Abstract

The human checkpoint kinase Chk1 has been suggested as a target for cancer treatment. Here, we show that a new inhibitor of Chk1 kinase, CEP-3891, efficiently abrogates both the ionizing radiation (IR)-induced S and G(2) checkpoints. When the checkpoints were abrogated by CEP-3891, the majority (64%) of cells showed fragmented nuclei at 24 hours after IR (6 Gy). The formation of nuclear fragmentation in IR-treated human cancer cells was directly visualized by time-lapse video microscopy of U2-OS cells expressing a green fluorescent protein-tagged histone H2B protein. Nuclear fragmentation occurred as a result of defective chromosome segregation when irradiated cells entered their first mitosis, either prematurely without S and G(2) checkpoint arrest in the presence of CEP-3891 or after a prolonged S and G(2) checkpoint arrest in the absence of CEP-3891. The nuclear fragmentation was clearly distinguishable from apoptosis because caspase activity and nuclear condensation were not induced. Finally, CEP-3891 not only accelerated IR-induced nuclear fragmentation, it also increased the overall cell killing after IR as measured in clonogenic survival assays. These results demonstrate that transient Chk1 inhibition by CEP-3891 allows premature mitotic entry of irradiated cells, thereby leading to accelerated onset of mitotic nuclear fragmentation and increased cell death.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15604269     DOI: 10.1158/0008-5472.CAN-04-2434

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  43 in total

1.  Exposure to acute hypoxia induces a transient DNA damage response which includes Chk1 and TLK1.

Authors:  Isabel M Pires; Zuzana Bencokova; Chris McGurk; Ester M Hammond
Journal:  Cell Cycle       Date:  2010-07-01       Impact factor: 4.534

2.  Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.

Authors:  Meredith A Morgan; Leslie A Parsels; Lili Zhao; Joshua D Parsels; Mary A Davis; Maria C Hassan; Sankari Arumugarajah; Linda Hylander-Gans; Deborah Morosini; Diane M Simeone; Christine E Canman; Daniel P Normolle; Sonya D Zabludoff; Jonathan Maybaum; Theodore S Lawrence
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

Review 3.  Chemotherapeutic approaches for targeting cell death pathways.

Authors:  M Stacey Ricci; Wei-Xing Zong
Journal:  Oncologist       Date:  2006-04

4.  Claspin operates downstream of TopBP1 to direct ATR signaling towards Chk1 activation.

Authors:  Shizhou Liu; Simon Bekker-Jensen; Niels Mailand; Claudia Lukas; Jiri Bartek; Jiri Lukas
Journal:  Mol Cell Biol       Date:  2006-08       Impact factor: 4.272

5.  Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial.

Authors:  Deepa Sampath; Jorge Cortes; Zeev Estrov; Min Du; Zheng Shi; Michael Andreeff; Varsha Gandhi; William Plunkett
Journal:  Blood       Date:  2005-11-17       Impact factor: 22.113

Review 6.  Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer.

Authors:  Shih-Hung Yang; Ting-Chun Kuo; Hsu Wu; Jhe-Cyuan Guo; Chiun Hsu; Chih-Hung Hsu; Yu-Wen Tien; Kun-Huei Yeh; Ann-Lii Cheng; Sung-Hsin Kuo
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

Review 7.  Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review.

Authors:  Meredith A Morgan; Leslie A Parsels; Jonathan Maybaum; Theodore S Lawrence
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

Review 8.  Impaired DNA damage response--an Achilles' heel sensitizing cancer to chemotherapy and radiotherapy.

Authors:  Zbigniew Darzynkiewicz; Frank Traganos; Donald Wlodkowic
Journal:  Eur J Pharmacol       Date:  2009-10-18       Impact factor: 4.432

Review 9.  New molecular targets in radiotherapy: DNA damage signalling and repair in targeted and non-targeted cells.

Authors:  Susanne Burdak-Rothkamm; Kevin M Prise
Journal:  Eur J Pharmacol       Date:  2009-10-14       Impact factor: 4.432

Review 10.  Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapy.

Authors:  Yingmei Wang; Ping Ji; Jinsong Liu; Russell R Broaddus; Fengxia Xue; Wei Zhang
Journal:  Mol Cancer       Date:  2009-02-13       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.